Author:
Balakrishnan Asha,Ledford Robert,Jaglal Michael
Publisher
Springer Science and Business Media LLC
Reference13 articles.
1. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014;16 Suppl 4:iv1–63.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.
3. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000;6(7):2585–97.
4. Merck Canada. Health Canada endorsed important safety information on TEMODAL® (temozolomide): association of TEMODAL® (temozolomide) with the risk of hepatic injury [news release]. 7 May 2014; http://www.merck.ca/Assets/News/TEMODAL%20HPC%20ENGLISH%20-%20FINAL.pdf . Accessed 15 January 2016.
5. Becker F, Hecht M, Schmidtner J, Semrau S, Fietkau R. Temozolomide-induced liver damage: a case report. Strahlenther Onkol. 2014;190(4):408–10.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献